Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2003-12-19
2011-11-29
Spector, Lorraine (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C514S001000, C514S017700, C514S018100
Reexamination Certificate
active
08066997
ABSTRACT:
The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
REFERENCES:
patent: 5516772 (1996-05-01), Glicksman et al.
patent: 6011004 (2000-01-01), Kessler et al.
patent: 6291247 (2001-09-01), Riopelle et al.
patent: 6300327 (2001-10-01), Knusel et al.
patent: 6333310 (2001-12-01), Presta et al.
patent: 6417159 (2002-07-01), Riopelle et al.
patent: 2001/0064695 (2001-11-01), Hadcock
patent: 0994188 (2000-04-01), None
patent: 9846254 (1998-10-01), None
patent: 0044396 (2000-08-01), None
patent: 0149313 (2001-07-01), None
patent: 02/096356 (2002-12-01), None
Jacobsen et al. The Journal of Biological Chemistry 276 (25): 22788-22796, published Jun. 2001.
Mazella J., Cellular Signalling, 13:1-6, Jan. 2001.
Pardridge W.M., Pharmaceutical Research 24(9): 1733-1744, Sep. 2007.
Shapiro et al., Expert Opinion in Biological Therapy, 6(5): 541-545, 2006.
Jacobsen et al., The Journal of Biological Chemistry, 271(49):31379-31383, Dec. 6, 1996.
Nielsen et al., The Journal of Biological Chemistry, 274(13):8832-8836, Mar. 26, 1999.
K.E. Neet and R.B. Campenot. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell. Mol. Life Sci. 58, 1021-1035 (2001).
Lee et al. Regulation of cell survival by secreted proneurotrophins. Science 294, 1945-1948 (Nov. 3, 2001).
Moses Chao and Mark Bothwell. Neurotrophins: to cleave or not to cleave. Neuron 33, 9-12 (Jan. 3, 2002).
Munck Petersen et al. Propeptide cleavage conditions sortilin
eurotensin receptor-3 for ligand binding. EMBO J. 18, 595-604 (1999).
Hampe et al. The genes for the human VPS10 domain-containing receptors are large and contain many small exons. Human Genetics 108, 529-536 (2001).
F.D. Miller and D.R. Kaplan. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell. Mol. Life Sci. 58, 1045-1053 (2001).
Jacobsen et al. Molecular characterization of a novel human hybrid-type receptor that binds the a2-macroglobulin receptor-associated protein. J. Biol. Chem. 271, 31379-31383 (Dec. 6, 1996).
Petersen et al. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J. Biol. Chem. 272, 3599-3605 (Feb. 7, 1997).
Nielsen et al. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 20, 2180-2190 (2001).
C. Wiesmann and A.M. de Vos. Nerve growth factor: structure and function. Cell. Mol. Life Sci. 58, 748-759 (2001).
Rattenholl et al. The pro-sequence facilitates folding of human nerve growth factor fromEscherichia coliinclusion bodies. Eur. J. Biochem. 268, 3296-3303 (2001).
Shirayama et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22, 3251-3261 (Apr. 15, 2002).
Lee et al. The uniqueness of being a neurotrophin receptor. Curr. Opin. Neurobiol. 11, 281-286 (2001).
Mazella et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 273, 26273-26276 (Oct. 9, 1998).
Barbara L. Hempstead. The many faces of p75NTR, Curr Opin. Neurobiol, Jun. 2002; 12(3):260-7.
Jacobsen et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J. Biol. Chem. 276, 22788-22796 (Jun. 22, 2001).
Thoenen, “the changing scene of neurotrophic factors”, Trends Neurosci. 14, 165-170 (1991).
Raffioni et al., “The Receptors for Nerve Growth Factor and Other Neurotrophins” Ann. Rev. Biochem. 62, 823-850 (1991).
Chao, “Neurotrophin Receptors: A Window into Neuronal Differentiation”, Neuron 9, 583-593 (1992).
Appel, S. H., “A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease,” Ann. Neurol. 10, 499-505 (1981).
Duman et al., “A Molecular and Cellular Theory of Depression”, Arch. Gen. Psychiatry 54, 597-606 (1997).
Fahnestock et al., “The Precursor Pro-Nerve Growth Factor is the Predominant Form of Nerve Growth Factor in Brain and is Increased in Alzheimer's Disease”, Mol. Cell. Neurosci. 18, 210-220 (2001).
Nykjaer et al., “Sortilin is essential for proNGF-induced neuronal cell death”, Nature vol. 427, p. 843-848, Feb. 26, 2004.
Nykjaer, et al., “p75NTR—live or let die”,Current Opinion in Neurobiology, vol. 15, pp. 49-57, 2005.
Antonelli et al., 2002, “Neurotensin Enhances Glutamate Excitotoxicity in Mesencephalic Neurons in Primary Culture”, Journal of Neuroscience Research 70: 766-773.
Boules et al., 2001, “Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats”,European Journal of Pharmacology 428; 227-233.
Airaksinen, et al. 2002. “The GDNF family: signalling. Biological functions and therapeutic value.”Nature Reviews—Neuroscience3:383-394.
Arshavsky, Y.I. 2006. “Alzheimer's disease, brain immune privelage and memory: a hypothesis.”J Neural Transm113:1697-1707.
Ballabh, et al. 2004. “The blood-brain barrier: an overview structure, regulation, and clinical implications.”Neurobiology of Disease16:1-13.
Bibel, et al. 1999. “Biochemical and functional interactions between the neurotrophin receptorstrkand p75NTR,”EMBO Journal18(3):616-622.
Bickel, Ulrich 1995. “Antibody delivery through the blood-brain barrier.”Advanced Drug Delivery Reviews15:53-72.
Bigner, et al. 1995. “Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F (ab′)2—a preliminary report.”Journal of Neuro-Oncology24:109-122.
Chao, Moses V. 2003. “Neurtrophins and their receptors: a convergence point for many signalling pathways.”Nature Reviews—Neuroscience4:299-309.
Chen, et al. 2008. “The proNGF-p75NTR-sortilin signalling complex as new target for the therapeutic treatment of Parkinson'd Disease.”CNS Neurol Disord Drug Targets7:512-523.
DeBoer, et al. 2006. “Blood-brain barrier dysfunction and recovery.”Journal of Neural Transmission113:455-462.
Dechant, George 2001. “Molecular interactions between neurotrophin receptors.”Cell Tissue Res305:229-238.
Fan, et al. 2008. “Differential effects of pro-BDNF on sensory neurons after sciatic nerve transection in neonatal rats.”European Journal of Neuroscience27:2380-2390.
French, et al. 2003. “Protein-based therapeutic approaches targeting death receptors.”Cell Death and Differentiation10:117-123.
Friden, et al. 1991. “Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.”Proc. Natl. Acad. Sci. USA88:4771-4775.
Lashford, et al. 1988. “A pilot study of131I monoclonal antibodies in the therapy of leptomeningeal tumors.”Cancer61:857-868.
Lee, et al. 2001. “Regulation of cell survival by secreted proneurotrophins.”Science194:1945-1948.
Neuwelt, Edward A. 2004. “Mechanisms of disease: the blood-brain barrier.”Neurosurgery54:131-142.
Nykjaer, et
Nykjaer Anders
Petersen Claus Munck
Buck Margaret M.
Kalinchak Stephen G.
Kohli Vineet
MacFarlane Stacey
Spector Lorraine
LandOfFree
Modulation of activity of neurotrophins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of activity of neurotrophins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of activity of neurotrophins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4258938